In a small study in metastatic ER+ breast cancer patients receiving a combination of tamoxifen, vorinostat, and pembrolizumab, increased PD-L1 expression on T cells (exhausted phenotype) was associated with improved progression-free survival with a trend towards improved overall survival [68]. The gene discussed is CD274; the disease is breast cancer.